Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 0.66 |
| ▸ | CCR5 | P51681 | 6/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13335050 | 1.00 | CCR2 (0.66) | CCR2CCR5KCNH2 | |
| SCHEMBL13335036 | 0.93 | CCR2 (0.66) | CCR2CCR5KCNH2 | |
| SCHEMBL3326128 | 0.93 | CCR2 (0.65) | CCR2CCR5KCNH2 | |
| SCHEMBL3327035 | 0.93 | CCR2 (0.66) | CCR2CCR5KCNH2 | |
| SCHEMBL13335048 | 0.93 | CCR2 (0.65) | CCR2CCR5KCNH2 | |
| SCHEMBL4333707 | 0.92 | CCR2 (0.78) | CCR2CCR5KCNH2 | |
| SCHEMBL13613480 | 0.92 | CCR2 (0.78) | CCR2CCR5KCNH2 | |
| SCHEMBL13335020 | 0.92 | CCR2 (0.65) | CCR2CCR5KCNH2 | |
| SCHEMBL3324806 | 0.92 | CCR2 (0.65) | CCR2CCR5KCNH2 | |
| SCHEMBL18265854 | 0.91 | CCR2 (0.63) | CCR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | claimed |
| US-8470827-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-06-25 | — | — | US | claimed |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2010-05-13 | — | — | US | claimed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CCR2 4/4885CCR5 1/4885KCNH2 3779/4885 |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | CCR2 4/4885CCR5 1/4885KCNH2 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.